ClinicalTrials.gg
Status unknownNCT05770648Updated Mar 15, 2023

A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Efficacy and Safety of the Transcatheter Tricuspid Valvuloplasty System in Patients With Severe or Above Tricuspid Regurgitation

An interventional study of Transcatheter Annuloplasty and The guidelines guide medication in Tricuspid Regurgitation, sponsored by Shanghai Huihe Medical Technology Co., Ltd. Status unknown. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by Shanghai Huihe Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

To evaluate the efficacy and safety of the transcatheter tricuspid valve ring system produced by Shanghai Huihe Medical Technology Co., Ltd. in the treatment of patients with severe or above tricuspid regurgitation who cannot be evaluated by clinicians for surgery.

02

Conditions studied

  • Tricuspid Regurgitation
03

In context

Tricuspid Valve Insufficiency

228 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

This study's planned enrollment of 64 is close to the median of 60 across 129 interventional studies indexed under Tricuspid Valve Insufficiency.

Browse Tricuspid Valve Insufficiency studies →

Lead sponsor

Shanghai Huihe Medical Technology Co., Ltd is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥60, male or female; (2) Patients with severe or above secondary tricuspid regurgitation (TR≥4+) (secondary tricuspid regurgitation: tricuspid regurgitation caused by right atrial disease, right ventricular cardiomyopathy, right ventricular myocardial infarction, left heart valve disease, congenital heart disease and other diseases); (3) A multidisciplinary cardiac team consisting of cardiovascular physicians, cardiovascular surgeons, imaging physicians, anesthesiologists, and at least 2 physicians considered the subjects to be at high risk for surgical procedures, i.e., EuroScore II was greater than 3.0%; (4) LVEF≥30%; (5) The subject voluntarily participates in the clinical trial and agrees or his guardian agrees to sign the ; (6) Symptoms of tricuspid regurgitation, such as chest tightness, asthma, shortness of breath, lower limb edema, ascites; (7) Grades 2 to 4, including Grades 2 and 4; (8) The optimal drug treatment for tricuspid valve ≥ 30 days and the patient's state was stable; (9) Patients with mitral regurgitation, atrial fibrillation, coronary artery disease, and heart failure should be treated for ≥ 30 days with medication or ≥ 30 days after instrument therapy and in stable condition.

Exclusion criteria

Exclusion Criteria:

  1. Patients with pure organic (i.e. primary) tricuspid regurgitation;
  2. Patients with pulmonary artery systolic blood pressure ≥60 mmHg;
  3. Patients with tricuspid valve prosthesis or plastic ring, or patients with tricuspid valve-related surgery;
  4. Patients with retrotricuspid annulus calcification;
  5. Evidence of intracardiac, jugular and superior vena cava masses, thrombus or growths;
  6. Patients with more than moderate aortic stenosis, mitral stenosis, aortic regurgitation, or mitral regurgitation;
  7. Patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
  8. Percutaneous coronary intervention within 1 month;
  9. Myocardial infarction or known unstable angina within the previous 1 month;
  10. cerebrovascular accidents occurred within the previous 3 months;
  11. Patients with active endocarditis or active rheumatic heart disease;
  12. Patients with coagulopathy, hypercoagulability or anemia ( \< 90 g/L);
  13. Patients in the acute infection stage or other severe infections;
  14. Patients with active peptic ulcer or active gastrointestinal bleeding;
  15. severe end-stage diseases (such as malignant tumors, severe lung diseases, liver diseases, renal failure) with a of less than 1 year;
  16. Patients with known allergy or to the raw material or drug (e.g. antiplatelet drugs, anticoagulants) of the test product;
  17. persons addicted to alcohol, drugs or drugs;
  18. Patients with cognitive impairment;
  19. A history of epilepsy or mental illness with primary and persistent seizures and poor drug control;
  20. Participate in any other clinical trial (other than a registered study) within 30 days prior to signing the ;
  21. have had a pacemaker (other than a leadless pacemaker) or a defibrillator implanted in the past, or plan to have a pacemaker (other than a leadless pacemaker) or a defibrillator implanted;
  22. tricuspid stenosis;
  23. Ebstain syndrome;
  24. esophageal esophageal echocardiography (TEE) and Trans thoracic echocardiography (TTE) were not esophageal esophageal tricuspid ring anatomy;
  25. Hemodynamic instability;
  26. Patients with chronic dialysis;
  27. Women who have planned to become pregnant during pregnancy, lactation or clinical study;
  28. Other conditions for which the investigator considers it inappropriate to participate in the clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    K-clipTM transcatheter annuloplasty system+Guideline Directed Medical Therapy GDMT

    Device: Transcatheter Annuloplasty

  • Other
    Guideline Directed Medical Therapy, GDMT

    Other: The guidelines guide medication

Interventions

  • DeviceTranscatheter Annuloplasty

    Under the guidance of ultrasound, the transcatheter tricuspid ring forming system accurately reaches the designated position of the tricuspid valve region through the jugular vein and superior vena cava approach. The expanded tricuspid ring tissue is clammed together with the clamping parts and anchor parts, and the circumference of the tricuspid ring is reduced, thus reducing the area of the opening of the tricuspid valve that cannot be closed originally, and achieving the purpose of minimally invasive treatment of tricuspid regurgitation.

  • OtherThe guidelines guide medication

    The guidelines guide medication

06

What researchers measure

Primary outcomes

  1. The percentage of subjects with no all-cause death, no heart failure readmitted, NYHA increased by one grade or more, and TR decreased ≥1+ within 6 months after randomization.

    The percentage of subjects with no all-cause death, no heart failure readmitted, NYHA increased by one grade or more, and TR decreased ≥1+ within 6 months after randomization.

    Time frame: Within 6 months of randomization

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2023; primary completion for Dec 2023, 9 months later.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 9 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2023
First posted
Mar 15, 2023
StartEst.
Mar 2023
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2024
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05770648
Lead sponsor
Shanghai Huihe Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Mar 15, 2023
Start date
Mar 2023 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 15, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion